Ethics Case Study: Ajit has been recently promoted as the Head of the Department of Weapon Sales (DWS) in the Ministry of Defence Production (MDP). His charter of duties includes international sales …

The decision

Production constraints permit one order. The question is framed as economics against ethics, but on these facts the two converge — and recognising that is the strongest move available.

The two buyers, compared

• Country A — sound technology base and a planned R&D collaboration for next-generation weapons; no security alliance, so no third-party leakage route; a defensive requirement against a troublesome neighbour; large order on long-term loan.
• Country B — military spending already displacing human development allocations; hosts a superpower's base and receives its grants; NPT non-signatory holding tactical nuclear weapons and delivery systems; supports guerrilla forces abroad; smaller order with some advance payment; simultaneously negotiating with another supplier.

The ethical issues

• End-use and diversion risk. B's support for guerrilla forces abroad is the single most serious fact in the case: weapons supplied to a state that arms non-state actors may reach those actors. This is a direct end-use violation risk, not a speculative one.
• Complicity. A supplier who foresees misuse and proceeds shares moral responsibility for the consequences.
• Development displacement. Selling to a state that already diverts human-development budgets to arms deepens harm to its own population.
• Proliferation and technology security. B is outside the NPT and hosts a foreign military base; sensitive technology could be exposed to both.
• Regional stability. Long-range artillery and missiles into an already militarised setting can trigger an arms spiral.
• The "someone else will sell anyway" argument. This is the classic rationalisation and it is ethically empty: the availability of another wrongdoer does not license the wrong. It also happens to be commercially weak, since B is negotiating elsewhere regardless.

Options before Ajit

• A. Sell to Country B. Merits: advance payment, quicker cash, possible goodwill with the economic bloc during FTA talks. Demerits: end-use and proliferation risk, reputational damage, technology exposure, and complicity in regional destabilisation.
• B. Sell to Country A. Merits: R&D partnership with long-term capability gain, no alliance-leakage route, defensive end-use, larger order building scale. Demerits: long-term loan defers revenue and carries credit risk.
• C. Refuse both pending capacity expansion. Merits: avoids all risk. Demerits: forfeits revenue, employment and strategic relationships for no ethical gain, since A raises no serious concern.
• D. Split the order. Merits: appears balanced. Demerits: production constraints forbid it, and it would take on B's risks anyway.

The recommendation: Country A

Option B should be selected, and the justification should rest on both grounds rather than on sentiment alone.

• Ethically — a defensive requirement, no record of arming non-state actors, no proliferation concern, and no foreign base through which technology could leak.
• Strategically — the R&D collaboration converts a one-time sale into a long-term capability partnership, which is worth more than one advance payment.
• Commercially — a larger order supports production scale; the long-term loan can be de-risked through export credit guarantees and sovereign instruments rather than treated as a reason to refuse.
• Reputationally — a supplier known for disciplined end-use scrutiny becomes more attractive to serious buyers, not less.

Balancing economic and strategic interest with ethics

• Institutionalise, do not improvise. Written end-use certificates, no-retransfer undertakings, and post-shipment verification rights turn a personal judgement into policy.
• Apply the existing framework — SCOMET controls, the Arms Trade Treaty criteria on diversion and human rights, and UN embargo checks — as a mandatory gate rather than a formality.
• Country risk assessment covering conflict involvement, non-state actor support, human rights record and treaty status, with inter-ministerial sign-off from MEA and defence.
• Sequence the questions. Legality first, then end-use risk, then strategic value, then commercial terms. Reversing that order is how bad sales get approved.
• Record dissent. If overruled at the political level, Ajit's duty is a written, reasoned note — the decision is the government's, the record is his.

Conclusion

Ajit should recommend Country A. The case is instructive precisely because the ethical choice is also the better strategic one: a partnership that builds capability beats a payment that buys risk. Where the two genuinely diverge, due diligence at every stage — which Ajit already knows to be pivotal — is what keeps a defence-export programme from becoming an instrument of somebody else's war. Our note on weapons and international regulation covers the treaty landscape.